Expression of PTEN helps determine metastatic behavior in a dose-dependent manner, and patients with lower PTEN and higher Entpd5 levels might represent a population at high risk (susceptibility) to developing the metastatic disease; these proteins may prove to be valuable biomarkers for predicting metastatic potential. This evidence concerns the gene PTEN and metastatic neoplasm.